Identification of Baseline Characteristics That Predict Good Outcome of alloHCT in Young CLL Patients - A Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Conference Correspondent - Conference Correspondent, ASH 2016 - Chronic Lymphocytic Leukemia

Patients with relapsed/refractory chronic lymphocytic leukemia (CLL) have excellent responses with kinase inhibitors such as ibrutinib or idelalisib + rituximab, or BCL2 inhibitors such as venetoclax, but patients with high-risk cytogenetics (del17p and/or del11q and TP53 mutation) do not seem to achieve long-term disease control and suffer relapse. However, allogeneic hematopoietic stem-cell transplantation (alloHCT) can result in sustained progression-free survival (PFS) independent of cytogenetic risk. As nonrelapse mortality (NRM) after alloHCT is partly age-dependent, alloHCT is preferably considered in younger, high-cytogenetic-risk CLL patients, but data of early NRM and longer-term PFS for this age group are lacking. Van Gelder and colleagues reported on a study that focused on younger allo-transplanted CLL patients (<50 years) in an EBMT registry cohort with additional data collection (n = 197; median follow-up, 90.4 months) to identify factors that predict low 2-year NRM and high 8-year PFS. They also studied the impact of del17p and del11q on PFS.

The most important prognostic factor for 2-year NRM in multivariate analysis was the donor HLA match: hazard ratio (HR) of 2.5 (95% confidence interval [CI], 1.1-5.4) for an HLA-matched unrelated donor, and HR of 4.0 (95% CI, 1.4-11.6) for an HLA-mismatched unrelated donor, both versus a matched sibling. Predictors for poor 8-year PFS were “no remission at the time of alloHCT” (HR, 1.7; 95% CI, 1.1-2.5) and partially HLA-mismatched unrelated donor (HR, 2.8; 95% CI, 1.5-5.2). High-risk cytogenetics did not have a significant impact on 8-year PFS. Previous autologous HCT was also identified as a risk factor for poor 8-year PFS (HR, 1.9; P=0.03). Based on the regression model, a reference patient was created with high-risk cytogenetics (del17p and/or del11q) and “good transplant” characteristics (remission at the time of alloHCT and HLA- and sex-matched sibling donor). The predicted 2-year NRM for this patient was 12.1% (95% CI, 2.5%-21.7%) and 8-year PFS was 53.5% (95% CI, 38.0%-69.0%). Such a low predicted NRM may keep up with the 9% “real-world” reported 1-year NRM of ibrutinib, and the 8-year PFS compares favorably to outcomes after using kinase inhibitors or venetoclax. In contrast, a patient with “poor transplant” characteristics (del17p and/or del11q, with no remission at the time of alloHCT, and an unrelated sex-mismatched donor) had a predicted 2-year NRM of 37% and 8-year PFS of approximately 20%. Taking into account the amount of uncertainty for predicting survival after alloHCT and also for the sequential administration of kinase inhibitors and venetoclax, alloHCT still remains a valid option for younger, high-cytogenetic-risk, refractory/relapsed CLL patients with a 10/10 HLA-allele–matched donor. Low-NRM risk factors can be identified in these “good transplant” patients, which will ensure very low NRM and 8-year PFS >50%.

Van Gelder M, et al. ASH 2016. Abstract 522.

Related Items
Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Improved Quality of Life in Adults with Acute Bacterial Skin and Skin Structure Infections with Omadacycline or Linezolid Therapy
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Omadacycline In Vitro Activity Against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Integrated Safety Summary of Omadacycline, A Novel Aminomethylcycline Antibiotic
December 2018 Vol 11, No 9 published on December 27, 2018 in Conference Correspondent
Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA
Conference Correspondent published on November 9, 2017 in ACR 2017, Conference Correspondent
Last modified: May 17, 2017
Copyright © Engage Healthcare Communications, LLC. All rights reserved.